Merus to Present at the Cantor Fitzgerald Global Healthcare Conference
UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and Head of Merus U.S., will present a company overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 4:00 p.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus’ website, www.merus.nl .
Investor and Media Inquiries:
Investor Relations and Corporate Communications
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
NEP Group25.6.2019 16:25:35 CEST | Pressemeddelelse
NEP Group Acquires HDR, Expanding Its Broadcast and Media Solutions Capabilities in Europe and Worldwide
Corel25.6.2019 15:02:09 CEST | Pressemeddelelse
Painter 2020 Empowers Digital Artists to Achieve Their Perfect Vision
Appian Corporation25.6.2019 15:02:09 CEST | Pressemeddelelse
Appian Announces Winners of its Annual Hackathon at Appian World
XBiotech Inc.25.6.2019 14:47:08 CEST | Pressemeddelelse
XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
Erytech Pharma S.A.24.6.2019 23:32:28 CEST | Pressemeddelelse
ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
Vricon24.6.2019 14:32:47 CEST | Pressemeddelelse
U.S. Army awards Vricon contract for One World Terrain
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum